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Inhibition of Fructose-1,6-bisphosphatase by a New Class of Allosteric
Effectors
Abstract
A highly constrained pseudo-tetrapeptide (OC252-324) further defines a new allosteric binding site located
near the center of fructose-1,6-bisphosphatase. In a crystal structure, pairs of inhibitory molecules bind to
opposite faces of the enzyme tetramer. Each ligand molecule is in contact with three of four subunits of the
tetramer, hydrogen bonding with the side chain of Asp187 and the backbone carbonyl of residue 71, and
electrostatically interacting with the backbone carbonyl of residue 51. The ligated complex adopts a
quaternary structure between the canonical R- and T-states of fructose-1,6-bisphosphatase, and yet a dynamic
loop essential for catalysis (residues 52-72) is in a conformation identical to that of the T-state enzyme.
Inhibition by the pseudo-tetrapeptide is cooperative (Hill coefficient of 2), synergistic with both AMP and
fructose 2,6-bisphosphate, noncompetitive with respect to Mg2+, and uncompetitive with respect to fructose
1,6-bisphosphate. The ligand dramatically lowers the concentration at which substrate inhibition dominates
the kinetics of fructose-1,6-bisphosphatase. Elevated substrate concentrations employed in kinetic screens
may have facilitated the discovery of this uncompetitive inhibitor. Moreover, the inhibitor could mimic an
unknown natural effector of fructose-1,6-bisphosphatase, as it interacts strongly with a conserved residue of
undetermined functional significance.
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A highly constrained pseudo-tetrapeptide (OC252–324)
further defines a new allosteric binding site located near
the center of fructose-1,6-bisphosphatase. In a crystal
structure, pairs of inhibitory molecules bind to opposite
faces of the enzyme tetramer. Each ligand molecule is in
contact with three of four subunits of the tetramer, hy-
drogen bonding with the side chain of Asp187 and the
backbone carbonyl of residue 71, and electrostatically in-
teracting with the backbone carbonyl of residue 51. The
ligated complex adopts a quaternary structure between
the canonical R- and T-states of fructose-1,6-bisphos-
phatase, and yet a dynamic loop essential for catalysis
(residues 5272) is in a conformation identical to that of
the T-state enzyme. Inhibition by the pseudo-tetrapeptide
is cooperative (Hill coefficient of 2), synergistic with both
AMP and fructose 2,6-bisphosphate, noncompetitive with
respect to Mg2, and uncompetitive with respect to fruc-
tose 1,6-bisphosphate. The ligand dramatically lowers the
concentration at which substrate inhibition dominates
the kinetics of fructose-1,6-bisphosphatase. Elevated sub-
strate concentrations employed in kinetic screens may
have facilitated the discovery of this uncompetitive inhib-
itor. Moreover, the inhibitor could mimic an unknown
natural effector of fructose-1,6-bisphosphatase, as it inter-
acts strongly with a conserved residue of undetermined
functional significance.
Fructose-1,6-bisphosphatase (D-fructose-1,6-bisphosphate
1-phosphohydrolase, EC 3.1.3.11; FBPase)1 catalyzes a tightly
regulated step of gluconeogenesis, the hydrolysis of fructose
1,6-bisphosphate (F16P2) to fructose 6-phosphate (F6P) and Pi
(1, 2). AMP and F26P2 (binding to allosteric and active sites,
respectively) inhibit FBPase, while simultaneously activating
its counterpart in glycolysis, fructose-6-phosphate 1-kinase (3,
4). Biosynthesis and degradation of F26P2 is subject to hormo-
nal control principally by glucagon and insulin (4, 5). F26P2
enhances the binding of AMP to FBPase by up to an order of
magnitude (6). Hence, although intracellular concentrations of
AMP remain relatively constant, AMP becomes a more potent
inhibitor of FBPase as concentrations of F26P2 increase. AMP
binds 28 Å away from the nearest active site and perhaps not
surprisingly inhibits catalysis noncompetitively with respect to
F16P2. Yet AMP is a competitive inhibitor of catalysis with
respect to essential divalent cations (Mg2, Mn2, or Zn2), all
of which are in proximity to (and probably coordinate with) the
1-phosphoryl group of F16P2 (710).
FBPase is a homotetramer (subunit Mr of 37,000 (11)) and
exists in at least two distinct quaternary conformations called
R and T (1214). AMP induces the transition from the active
R-state to the inactive (or less active) T-state. Substrates or
products in combination with metal cations stabilize the R-
state conformation. A proposed mechanism for allosteric regu-
lation of catalysis involves three conformational states of loop
5272 called engaged, disengaged, and disordered (15). AMP
alone or with F26P2 stabilizes a disengaged loop (16, 17),
whereas metals with products stabilize an engaged loop (10,
1719). In active forms of the enzyme, loop 5272 probably
cycles between its engaged and disordered conformations (15,
18). Fluorescence from a tryptophan reporter group at position
57 is consistent with the conformational states for loop 5272,
observed in crystal structures (20, 21). Presumably, the en-
gaged, disengaged, and disordered conformations of loop 5272
are possible in both the R- and T-states of FBPase, but only the
engaged and disordered conformers of the R-state, and the
disengaged conformer of the T-state, have been reported in
crystalline complexes (17, 18, 22, 23).
A recent report (24) in the literature identifies a new inhib-
itor site on FBPase, distinct from the active and the AMP-
binding sites. The new family of anilinoquinazoline inhibitors
was discovered by a search for potential drugs in the treatment
of non-insulin-dependent diabetes. Although the site of binding
on FBPase is clear, the kinetic mechanism of inhibition for this
new class of inhibitor was not reported. Independent of the
efforts above, a screen for new inhibitors of FBPase resulted in
the discovery of a chemically distinct molecule (OC252–324,
* This work was supported in part by National Institutes of Health
Research Grant NS 10546, Small Business Innovation Research Grants
R43 DK57342-01 (phase 1) and R44 DK57342-02 (phase 2), and Dr.
Barry Toyonaga, Ontogen Corp. The costs of publication of this article
were defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
The atomic coordinates and structure factors (code 1Q9D) have been
deposited in the Protein Data Bank, Research Collaboratory for Struc-
tural Bioinformatics, Rutgers University, New Brunswick, NJ
(http://www.rcsb.org/).
¶ Present address: Johnson & Johnson Pharmaceutical Research and
Development, L. L. C., 3210 Merryfield Row, San Diego, CA 92121.
 Present address: Tularik Inc., 1120 Veterans Blvd., South San Fran-
cisco, CA 94080.
** Present address: Dihedron Corp., 10931 North Torrey Pines Rd.,
Ste. 104, La Jolla, CA 92037.
‡‡ Present address: Ferring Research Institute Inc., 3550 General
Atomics Court, San Diego, CA 92121.
§§ Present address: Cheminomics Group, 10819 Red Rock Dr., San
Diego, CA 92131.
¶¶ To whom correspondence should be addressed. Tel.: 515-294-6116;
Fax: 515-294-0453; E-mail: honzatko@iastate.edu.
1 The abbreviations used are: FBPase, fructose-1,6-bisphosphatase;
F16P2, fructose 1,6-bisphosphate; F6P, fructose 6-phosphate; F26P2,
fructose 2,6-bisphosphate.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 278, No. 51, Issue of December 19, pp. 51176–51183, 2003
© 2003 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org51176
 at IO
W
A
 STA
TE U
N
IV
 on M
arch 28, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
hereafter OC252, Fig. 1) that targets the same binding site on
FBPase. Inhibition of FBPase by OC252 is cooperative (Hill
coefficient of 2), synergistic with AMP and F26P2, noncompet-
itive with respect to Mg2, but uncompetitive with respect to
F16P2. OC252 greatly decreases the concentration at which
substrate inhibition dominates the kinetics of FBPase. The
crystal structure reveals a pair of OC252 molecules bound to
each face of an FBPase tetramer. The quaternary conformation
of the tetramer differs from the canonical R- and T-states,
observed in the absence and presence of AMP, respectively, yet
the loop (residues 5272) is in its disengaged conformation. A
strong hydrogen bond between OC252 and the side chain of a
conserved aspartate residue of undetermined functional signif-
icance suggests the possibility of a binding site recognized by
an unknown natural effector.
EXPERIMENTAL PROCEDURES
Materials—F16P2, F26P2, NADP
, and AMP were purchased from
Sigma. Glucose-6-phosphate dehydrogenase and phosphoglucose
isomerase came from Roche Applied Science. Other chemicals were of
reagent grade or the equivalent. QSW-HR high pressure liquid chro-
matography resin came from Toso-Hass Bioseparations. FBPase-defi-
cient Escherichia coli strain DF 657 came from the Genetic Stock
Center at Yale University. Plasmids used in the expression of wild-type
FBPase came from a previous investigation (20). The inhibitor OC252
was provided by Ontogen Corp. (Carlsbad, CA).
Expression and Purification of Wild-type FBPase—Separate prepa-
rations of enzyme were used for the structural and kinetics investiga-
tions. Recombinant FBPase was expressed in a strain of E. coli deficient
in endogenous FBPase and then purified to homogeneity. Cell-free
extracts of the wild-type FBPases were subjected to heat treatment
(65 °C for 5 min), followed by centrifugation. For enzyme used in kinet-
ics investigations, the supernatant solution was loaded onto a Cibacron
Blue-Sepharose column, previously equilibrated with 20 mM Tris-HCl,
pH 7.5. FBPases were eluted from that column with 1 mM AMP and 20
mM Tris-HCl, pH 7.5. The eluent from the first column was loaded
directly onto a DEAE-Sepharose column and then eluted with a NaCl
gradient (0–0.3 M). The purified enzyme was dialyzed extensively
against 20 mM Tris-HCl, pH 7.5. For crystallization experiments, after
volume reduction by pressure concentration through an Amicon PM-30
membrane, the supernatant solution from centrifugation was passed
through a CM-Sepharose column using a NaCl gradient (20400 mM)
in 10 mM Tris malonate, pH 6.0, and then dialyzed against KPi (20 mM,
pH 7.0). Purity and protein concentrations of FBPase preparations were
confirmed by SDS-PAGE (25) and the Bradford assay (26), respectively.
Kinetic Experiments—Assays for the determination of specific activ-
ity, kcat, and activity ratios at pH 7.5 and 9.5 employed the coupling
enzymes, phosphoglucose isomerase and glucose-6-phosphate dehydro-
genase (1). The reduction of NADP to NADPH was monitored by
absorbance spectroscopy at 340 nm. All other assays used the same
coupling enzymes, but monitored NADPH production by its fluores-
cence emission at 470 nm, using an excitation wavelength of 340 nm.
Kinetic assays were performed at room temperature (22 °C). Data fit-
ting and analysis used the program DYNAFIT (27).
Crystallization of the Product Complex—Crystals of FBPase grew by
the method of hanging drops. Equal parts of a protein solution (FBPase
(10 mg/ml), KPi, pH 7.4 (10 mM), MgCl2 (5 mM), F6P (5 mM), and OC252
(2 mM)) and a precipitant solution (Tris malonate, pH 7.4 (2.5 mM),
polyethylene glycol 3350 (6% w/v)) were combined in a droplet of 4 l
total volume. Wells contained 500 l of the precipitant solution. Crys-
tals of dimensions 0.4  0.4  0.3 mm grew in approximately 3 days at
20 °C. OC252 is relatively insoluble in aqueous solutions. Approxi-
mately 10 mg of pure inhibitor was dissolved initially in acetone, and
appropriately measured aliquots were distributed to empty vials. The
acetone was removed by evaporation, and the protein solution above
was added. The inhibitor dissolved after a brief time interval to provide
the clear protein solution used in the crystallization experiments.
Data Collection—Data were collected at Iowa State University on a
rotating anode/Siemens area detector at 120 K, using CuK radiation
passed through a graphite monochromator. Data were reduced by XEN-
GEN (28).
Structure Determination, Model Building, and Refinement—Crystals
grown for the present study are isomorphous to the AMP-Zn2-product
complex (17). Phase angles, used in the generation of initial electron
density maps, were based on model 1EYJ of the Protein Data Bank,
from which water molecules, metal cations, small molecule ligands, and
residues 5272 had been omitted. Residues 5272 were built into the
electron density of omit maps, with reference to the C coordinates of
loop 5272 from the AMP complex (17), using the program XTALVIEW
FIG. 2. Synergism in the inhibition of FBPase by OC252, F16P2,
and AMP. OC252 concentrations vary from 0 to 10 M. Symbols rep-
resent relative velocities for OC252 alone (Œ), OC252 with 0.45 M
F26P2 (), and OC252 with 1.5 M AMP (). Assays use 50 mM Hepes,
pH 7.5, with 0.5 mM MgCl2 and 20 M F16P2. Curves are fits to the data
using Equation 1.
FIG. 1. Covalent structure of OC252. Atoms C-8, C-10, C-12, and
C-14 correspond to C atoms of residues labeled 14. Atoms C-8, C-10,
and C-12 adopt the L-configuration of a common amino acid. Residues 1
and 4 have tyrosyl side chains; residue 2 has a phenylalanine side chain
bridged by a methylene group to its amide nitrogen atom (N-1), and
residue 3 has an n-propyl side chain. In its crystalline complex, a close
contact between atoms N-3 and O-3 infers a strong intramolecular
hydrogen bond. The electronic resonance state of the bond between
atoms N-2 and C-11 is speculative but would account for the close
contact between backbone carbonyl 51 (from FBPase) and atom N-2
through enhanced electrostatic interactions.
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(29) and a Silicon Graphics work station. A molecule of Pi and of F6P
and two magnesium cations were added to omit electron density of the
active site. Strong electron density remained, however, near the center
of the tetramer, which easily accommodated a molecule of OC252. The
resulting model underwent refinement, using CNS (30) with force con-
stants and parameters of stereochemistry from Engh and Huber (31). A
cycle of refinement consisted of slow cooling from 2500 to 300 K in steps
of 25 K, followed by 120 cycles of conjugate gradient minimization, and
concluded by the refinement of individual thermal parameters. Ther-
mal parameter refinement employed restraints of 1.5 Å2 on nearest
neighbor and next-to-nearest neighbor main chain atoms, 2.0 Å2 on
nearest neighbor side chain atoms, and 2.5 Å2 on next-to-nearest neigh-
bor side chain atoms.
In subsequent cycles of refinement, water molecules were fit to
difference electron density of 2.5 or better and were added until no
significant decrease was evident in the Rfree value. Included in the final
model were water molecules that make suitable donor-acceptor dis-
tances to each other and the protein and have thermal parameters
under 60 Å2.
RESULTS
Expression and Purification of Wild-type FBPase—Expres-
sion and isolation procedures described above provide FBPase
in at least 95% purity, as judged by SDS-PAGE (data not
shown). The kcat value (22  1 s
1) and the ratio of specific
activities at pH 7.5 to 9.5 (3.3) indicate high purity and little or
no proteolysis of the purified enzyme, consistent with the re-
sults from electrophoresis.
Kinetics Experiments—By using fixed concentrations of
MgCl2 (0.5 mM, approximately the Ka for Mg
2) and F16P2 (20
M, saturating), initial velocities vary as the inverse square of
OC252 concentration (Hill coefficient of 1.97  0.1) with an I0.5
(concentration of OC252 that causes 50% inhibition) of 1.87 
0.07 M (Fig. 2). F26P2, AMP, and OC252 inhibit FBPase
synergistically; I0.5 values for OC252 are 0.63  0.04 M (Hill
coefficient, 1.6  0.1) in the presence of 1.5 M AMP and 0.48 
0.01 M (Hill coefficient, 1.7  0.1) in the presence of 0.45 M
F26P2. The numerical values above result from a fit of data to
Equation 1,
Vo/Vm  I0.5/(I0.5  In) (Eq. 1)
where n is the Hill coefficient, Vm the initial velocity in the
absence of inhibitor, Vo the initial velocity at a specific inhibitor
concentration, I the concentration of OC252, and I0.5 the con-
centration of OC252 that causes 50% inhibition.
Kinetics data were taken over broad concentration ranges of
Mg2 (0.25 mM), F16P2 (120 M), and OC252 (020 M) in
order to determine the kinetic mechanism of inhibition. Plots of
reciprocal velocity against 1/[Mg2]2 (F16P2 saturating, but
below concentrations that cause significant substrate inhibi-
tion) and 1/[F16P2] (Mg
2 saturating) indicate noncompetitive
inhibition with respect to Mg2 and uncompetitive inhibition
with respect to F16P2 (Fig. 3). As is evident from Fig. 3A,
substrate inhibition increases significantly with rising inhibi-
tor concentration. Data from Fig. 3A were fit to nine different
TABLE I
Hypothetical models of inhibition of FBPase by OC252
In the absence of inhibitor and substrate, all enzyme is in an
E(Mg2)2 complex (conditions of saturating Mg
2). Each model as-
sumes a Hill coefficient of 2 for OC252 inhibition and rapid equilibrium
kinetics, in which the conversion of E(Mg2)2F16P2 to E(Mg
2)2
F6PPi is rate-limiting. The Michaelis equilibrium, E(Mg
2)2  F16P2
N E(Mg2)2F16P2, is common to all mechanisms, and is not included.
M, S, and I below represent Mg2, F16P2, and OC252, respectively.
RMSD is the root mean squared deviation between observed velocities
and those calculated from the model.
FIG. 3. Kinetic mechanism of inhibition of FBPase by OC252.
A, data are taken at 120 M F16P2 in 50 mM Hepes, pH 7.5, with 5 mM
MgCl2. Curves are fits to the data using Equation 3. B, data are taken
at 0.15 mM Mg2 (corrected for chelation by EDTA) in 50 mM Hepes,
pH 7.5, with 20 M F16P2. Curves are fits to the data using Equation 4.
Fructose-1,6-bisphosphatase51178
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kinetic models using the program DYNAFIT (27), combining
mechanisms of competitive, noncompetitive, and uncompeti-
tive inhibition by OC252, with and without pathways for in-
hibitor-induced substrate inhibition or partial inhibitor-in-
duced substrate inhibition (Table I). (Inhibitor-induced
substrate inhibition requires the binding of OC252 prior to the
binding of the inhibitory F16P2 molecule. Inhibitor-induced
partial substrate inhibition allows turnover of the substrate-
inhibited enzyme at a reduced maximal velocity.) All successful
kinetic models include the association of two molecules of
OC252 with an E(Mg2)2F16P2 complex to form an
E(Mg2)2F16P2(OC252)2 complex (uncompetitive inhibition
with respect to F16P2). The latter complex induces the forma-
tion of E(Mg2)2(F16P2)2(OC252)2 (inhibitor-induced sub-
strate inhibition). Parameters representing the formation of an
E(Mg2)2(OC252)2 complex (which would result in competi-
tive, noncompetitive, or mixed inhibition with respect to F16P2
and/or the turnover of the E(Mg2)2(F16P2)2(OC252)2 com-
plex (inhibitor-induced partial substrate inhibition) are not
justified on the basis of F tests. Hence, model H of Table I
represents the data at saturating Mg2 with the fewest param-
eters. Scheme I then represents the kinetic mechanism of in-
hibition at all concentrations of the relevant ligands.
From Scheme I we derived the following relationship (Equa-
tion 2) assuming rapid-equilibrium kinetics under initial veloc-
ity conditions,
1/V 1/Vm1Ka/A2 Kb/B KiaKb/A2B KaI2/KiA2
 I2/Kii1 B/Kiis)) (Eq. 2)
where A, B, and I are concentrations of free Mg2, F16P2, and
OC252, respectively; Vm is the maximal velocity, and Kia, Ka,
Kb, Ki, Kii, and Kiis are dissociations constants for two
Mg2 atoms from the E(Mg2)2 complex, for two Mg
2 atoms
from the E(Mg2)2F16P2 complex, for F16P2 from the
E(Mg2)2F16P2 complex, for two OC252 molecules from the
EF16P2(OC252)2 complex, for two molecules of OC252
from the E(Mg2)2F16P2(OC252)2 complex, and for the
second (inhibitory) molecule of F16P2 from the
E(Mg2)2(F16P2)2(OC252)2 complex, respectively. Equation 2
simplifies under conditions of saturating Mg2 to Equation 3,
1/V 1/Vm1Kb/B I2/Kii1 B/Kiis (Eq. 3)
which is used in the determination of Vm, Kb, Kii, and Kiis from
data in Fig. 3A. Under these conditions, [F16P2]Kb, Equa-
tion 2 simplifies to Equation 4,
1/V 1/Vm1Ka/A2  KaI2/KiA2 I2/Kii1 B/Kiis)) (Eq. 4)
which is used in the determination of Vm, Ka, and Ki from data
in Fig. 3B using numerical values for Kii and Kiis from Equation
3. Values for kinetic parameters are in Table II.
OC252 Complex of FBPase (Protein Data Bank Code
1Q9D)—Crystals grown in the presence of OC252 belong to the
space group P21212 (a  58.86, b  166.25, c  80.27), and are
isomorphous to those of AMP complexes of FBPase (17). Two
subunits of FBPase are in the asymmetric unit of this crystal
form. C coordinates of the independent subunits superim-
posed with a root mean square deviation of 0.38 Å, using a
subset of residues (3349, 75265, and 272330), which do
not exhibit significant tertiary conformational differences be-
tween the T- and R-state subunits of FBPase (10). Regions of
TABLE II
Kinetic parameters determined by fits of Equations 3 and 4 to the
data of Fig. 3. Maximum velocity is expressed in terms of the change
in fluorescence (units not defined) with time
Parameter Numerical value
Equation 3
Vm 18.4  0.3 	F/s
Kb 2.16  0.08 M
Kii 25  2 M
2
Kiis 7.6  1 M
Equation 4
Vm 17.1  0.8 	F/s
Ka 0.38  0.02 mM
2
Ki 3.65  0.6 M
2
TABLE III
Statistics of data collection and refinement for the
OC252-FBPase complex
Resolution (Å) 2.35
No. measurements 94,949
No. unique reflections 28,849
Completeness of data
Overall 87.5
Last shell (2.44-2.35 Å) 65.5
Rsym
a 5.9
No. reflections in refinementb 27,163
No. atoms 5434
No. solvent sites 290
R-factorc 0.191
Rfree
d 0.246
Mean thermal parameters
(Å2)
Protein 21.1
Mg2 22.1
F6P 24.5
Pi 50.1
OC252 13.6
Root mean square deviations
Bond lengths (Å) 0.012
Bond angles (degree) 1.7
Dihedral angles (degree) 24.1
Improper angles (degree) 5.74
a Rsym  
j
iIij Ij/
i
jIij, where i runs over multiple observations
of the same intensity and j runs over crystallographic unique intensi-
ties.
b All data are in the resolution range of 50-2.35 Å.
c R-factor  
Fobs  Fcalc/
Fobs, where Fobs  0.
d R-factor based upon 10% of the data randomly culled and not used
in the refinement.
TABLE IV
Root mean squared deviations (in Å) in superpositions of C1-C2
subunits and tetramers (boldface) of FBPase
All superpositions employ C atoms of residues 33-49, 75-265, and
272-330. The R-state and T-state structures are from the Protein Data
Bank, accession labels 1CNQ and 1EYK, respectively.
T-state OC252 complex
R-state 2.71/0.578 2.16/0.481
T-state 0.703/0.332
SCHEME I
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weak or absent electron density include residues 18 and
6370. The model begins at residue 9 and continues to the last
residue of the sequence, but segment 6370 is unreliable, as
evidenced by high thermal parameters. Thermal parameters
vary from 5 to 57 Å2. As determined by PROCHECK (32), the
model has stereochemistry generally comparable with that of
structures derived from data of nominal resolution 2.0 Å. Sta-
tistics for data collection and refinement are in Table III, and
an overview of the complex appears in Fig. 4.
Although the two subunits of the OC252 complex are similar,
the ligation of each active site by metals differs. In the subunit
labeled chain B, strong electron density is at metal site 1. The
thermal parameter of Mg2 at full occupancy here refines to a
value of 10 Å2, which is significantly less than the average
value (20 Å2) for atoms of the protein ligated to that metal.
Hence Mg2 and a heavier metal (Zn2, on the basis of prior
experience (19)) probably co-occupy site 1 in chain B. Site 2 of
chain B has diffuse electron density that may represent disor-
dered water molecules or the combination of water molecules
and Mg2 at low occupancy; Mg2 at full occupancy refined at
metal site 2 with a thermal parameter of 32 Å2. In the subunit
labeled chain A, Mg2 refines with thermal parameters of 18
and 29 Å2 at sites 1 and 2, respectively. Metal site 2 in chain A
may be occupied partially by Mg2. The conformations of side
chains near metal site 2 also differ in each of the symmetry
unique subunits of the crystal. In addition, molecules of Pi are
at partial occupancy at each active site, but molecules of F6P
are at full occupancy.
OC252 is arguably a highly constrained pseudo-tetrapeptide
(Fig. 1); the first and fourth “residues” have tyrosyl side chains,
a methylene group in residue 2 covalently bridges the phenyl-
alanyl side chain to its amide nitrogen, and an n-propyl group
is the side chain of residue 3. The N-2 atom of OC252 corre-
sponds to the backbone nitrogen atom of the first and third
residues, and the terminal carboxyl group is absent. Atoms C-8,
C-10, and C-12 have the L-configuration of a common amino
FIG. 4. OC252-FBPase complex. The
top panel gives orthogonal views of the
complex showing FBPase as a ribbon with
atoms of Mg2, F6P, Pi, and OC252 as
spheres. The bottom panel shows electron
density covering a pair of OC252 mole-
cules from an omit map contoured at a
level of 1 with a cut-off radius of 1 Å
(bottom). This drawing was prepared with
MOLSCRIPT (41).
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acid. In their FBPase complex, two molecules of OC252 are in
mutual contact, related to each other by the molecular 2-fold
axis that projects through the face of the FBPase tetramer.
Most of the contacts between inhibitor and protein are apolar;
however, the phenol oxygen atoms of residues 1 and 4 of OC252
hydrogen-bond with backbone carbonyl 71 and the side chain of
Asp187, respectively. Furthermore, the C—O bond axis of back-
bone carbonyl 51 is normal to the plane defined by atoms C-8,
N-2, C-11, and C-12 of OC252, with its oxygen atom 3.2 Å from
atom N-2. The latter suggests an electronic resonance state of
the bound OC252 molecule that stabilizes this close contact
(Fig. 1).
Although the OC252 and AMP crystalline complexes are
isomorphous, the two FBPase tetramers adopt different qua-
ternary conformations. Superpositions of C1C2 subunit pairs
from the OC252, T-state, and R-state complexes give compara-
ble root mean squared deviations (Table IV). (See Fig. 4 for the
convention adopted in the labeling of subunits.) On the other
hand, superpositions of tetramers give significantly larger de-
viations, suggesting different quaternary structures. Indeed,
the C3C4 subunit pair in the OC252 complex rotates 14°
relative to the C1C2 subunit pair, falling some 3° short of the
canonical T-state (Fig. 5). Hereafter, we refer to the quaternary
state of FBPase induced by OC252 as the I-state.
The I-state must be due to the specific effects of the OC252
inhibitor. First, the conditions of crystallization for the T-, R-,
and I-states of FBPase differ only by the presence or absence of
allosteric effectors. The T-state crystallizes in the presence of
AMP (17), the I-state in the presence of OC252, and the R-state
in the absence of allosteric effectors (10, 17). Hence, ligation of
FBPase by OC252 favors neither the T- nor R-state. OC252,
however, stabilizes the disengaged conformation of loop 5272,
which prior to this work has been seen only in AMP-ligated
complexes. Moreover, rotation of the side chain of His55 about
its CC bond eliminates the only unfavorable contact between
OC252 and the superimposed T-state. Hence, OC252 could bind
to T-state FBPase in an AMPOC252 complex. On the other
hand, residues 5156 of the engaged loop (a conformation ob-
served only in the R-state) and the side chain of the poorly
ordered Phe6 partially fill the OC252 binding pocket in the
R-state. OC252 may still bind to the R-state enzyme, but at the
very least loop 5272 cannot be in its engaged conformation.
Although loop 5272 represents the largest conformational
difference at the tertiary level between subunits in the T- and
R-states of FBPase, other significant changes occur in the
vicinity of the AMP pocket. Helices H1 and H2 are 2 Å closer
to each other in the T-state than in the R-state, a difference
attributed to the binding of AMP (14). Comparison of I-state
and T-state subunits, however, presents a more complex sce-
nario. Relative to the T-state, the binding site for the base of
AMP is hindered sterically in the I-state. The interaction of
backbone amide 17 and Thr31 with the 6-amino group of AMP
would force the adenine base into an unfavorable contact (2.5
Å) with the C atom of Glu20 (Fig. 6). Evidently, a conforma-
tional change in the last two turns of helix H1 relaxes this
unfavorable contact but in so doing perturbs Glu19 and Arg22.
The side chains of Glu19 and Arg22 are in contact with residues
2628 of a neighboring subunit (C1C4/C2C3 interface).
Residues 2628 in turn hydrogen-bond with the 5-phosphoryl
group of AMP. Evidently, the collapse of helices H1 and H2
onto the AMP pocket then is complete in the I-state. Further
progress toward the T-state then requires hydrogen bonds of
the 6-amino group of AMP to force conformational changes at
the C1C4/C2C3 interface.
DISCUSSION
OC252 and anilinoquinazolines (24) recognize a common site
on FBPase, but the binding modes of these inhibitors differ
substantially. Each inhibitor-type binds as a pair, but bound
anilinoquinazoline and OC252 molecules have orthogonal ori-
entations; two aniliquinazoline molecules overlap distinct moi-
eties of a single OC252 molecule (Fig. 7). The quinazoline
moiety of the anilinoquinazoline overlaps residues 1 and 2 of
OC252, whereas the phenylthiazole moiety overlaps residue 3
of the other OC252 molecule. No part of the anilinoquinazoline
molecule corresponds to residue 4 of OC252, the side chain of
which hydrogen-bonds Asp187. In fact, the phenylthiazole moi-
ety through stacking interactions positions the side chain of
His55 over the pocket occupied by the tyrosyl side chain of
OC252 residue 4. The anilinoquinazoline is roughly crescent-
shaped; the ends of the crescent contact the surface of the
FBPase tetramer with the curve of the crescent projecting
outward. Residues 3 (n-propyl side chain) and 4 (tyrosyl side
chain) of OC252, on the other hand, penetrate the interior of
the tetramer. Hence, the number of contacts between OC252
and FBPase greatly exceeds that of the anilinoquinazoline.
Each OC252 molecule interacts with residues from three of
four subunits of FBPase, whereas each anilinoquinazoline mol-
ecule interacts with residues from a pair of subunits (Fig. 7).
Curiously, despite all the differences above, both inhibitor
types foster stabilizing interactions with backbone carbonyl 51
of FBPase. For the anilinoquinazoline, the hydroxyl group of
the phenylthiazole moiety hydrogen-bonds directly with back-
bone carbonyl 51, whereas atom N-2 of the OC252 molecule is
in a possible electrostatic contact with the oxygen atom of the
backbone carbonyl 51.
Inhibitors of wild-type FBPases are either competitive (such
as F26P2) or noncompetitive (such as AMP) with respect to
F16P2. Uncompetitive inhibition of FBPase by OC252 with
respect to the substrate is unusual but not unprecedented. The
mutation of Arg49 to cysteine changes the kinetic mechanism of
AMP inhibition with respect to F16P2 from noncompetitive to
uncompetitive, but retains the competitive mechanism of AMP
inhibition with respect to Mg2 (33). Evidently, AMP best
inhibits Cys49 FBPase at low concentrations of Mg2 and at
high concentrations of F16P2. The side chain of Arg
49 partici-
FIG. 5. Superposition of the OC252 complex onto the T- and
R-states of FBPase. C atoms of residues 3349, 75265, and
272330 of subunits C1 and C2 are the basis for superposition. Pre-
sented are displacements of C atoms in -strands of the AMP domain
of subunits C3 and C4 in the OC252 complex (heavy lines) relative to
those of the T-state (A) and R-state (B).
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pates in several hydrogen-bonded interactions in the T-state of
FBPase, and has low thermal parameters (2025 Å2), but is
less ordered in the R-state, having thermal parameters of
4045 Å2 (17). The loss of Arg49 by mutation then may desta-
bilize the T-state relative to the R-state. AMP may bind to
Cys49 FBPase in the R-state but not cause a transition to the
T-state. F16P2 could stabilize an intermediate state of Cys
49
FBPase that facilitates the binding of AMP, and indeed, F16P2
and AMP in the absence of metals bind synergistically to wild-
type FBPase (34). An uncompetitive pattern of inhibition would
result then if subsequent AMP ligation of this F16P2-stabilized
state caused a transition to the T-state.
The quaternary state of FBPase stabilized by OC252 (the
I-state) may be similar to this hypothetical F16P2-stabilized
state of Cys49 FBPase. First, uncompetitive inhibition by
OC252 with respect to F16P2 reflects binding synergism; liga-
tion of the active site by F16P2 enhances the affinity of OC252
for its binding site (see Scheme I). Moreover, the binding of
OC252 induces F16P2 inhibition (Fig. 3B). Binding synergism
between OC252 and F16P2 would occur if each ligand were to
bind at distinct sites and stabilize a common conformational
state of FBPase. Hence, the I-state observed in the OC252
complex may be similar to the quaternary state of FBPase in
the presence of inhibitory concentrations of substrate. Ligation
of FBPase by OC252 excludes the engaged conformation of loop
5272, which is presumably required for catalysis. The I-state
itself may disfavor the engaged conformation of loop 5272,
thereby accounting for the phenomenon of substrate inhibition
of FBPase at concentrations of F16P2 in excess of 30 M.
The I-state may also be the basis for synergistic inhibition of
FBPase by OC252 and F26P2. Elevated levels of F26P2 (200
M) cause a transition from the loop-engaged R-state to a
conformation similar but not identical to the T-state, as meas-
ured by fluorescence from a Trp57 reporter group (20). Perhaps
high concentrations of F26P2 stabilize the I-state, and indeed
the tetramer does adopt the I-state in a preliminary crystal
structure of an F26P2-FBPase complex.
2 As OC252 and F26P2
stabilize the same quaternary conformation by interactions at
topologically distinct sites, they must exhibit functional syner-
gism in rapid equilibrium kinetics.
An explanation of the synergism between AMP and OC252 is
only slightly more complex. OC252 clearly excludes the en-
gaged conformer of loop 5272 and evidently stabilizes the
disengaged loop present in the AMP complex of FBPase. More-
over, the I-state probably lies on or near the free energy path-
way connecting the R- and T-states. So by stabilizing the I-
state, OC252 does much of the work that AMP normally
accomplishes in driving the R- to T-state transition.
But is the I-state of FBPase an appropriate target for the
development of new drugs? Estimates of the free concentra-
tions of F16P2 in liver (1 M (35)) are well below those that
cause substrate inhibition (30 M and above) of FBPase. Sim-
ilarly, concentrations of F26P2 (200 M) and products (250 M)
that stabilize the I-state in fluorescence experiments are far in
excess of those in vivo. On the other hand, AMP and F26P2 are
the principal metabolic effectors of FBPase. Given that OC252
inhibits FBPase synergistically with AMP and F26P2 at phys-
iological concentrations of substrate, the central allosteric
2 J.-Y. Choe and R. B. Honzatko, unpublished results.
FIG. 6. Stereoviews of the AMP
binding pocket in different quater-
nary states of FBPase. Dashed lines
represent contacts between the AMP mol-
ecule and the T-state complex (fine lines)
and the superimposed OC252 complex
(heavy lines).
FIG. 7. Comparison of the binding modes of OC252 and an
anilinoquinazoline inhibitor. The top panel shows the superposition
of OC252 and anilinoquinazoline molecules (using FBPase tetramers as
the basis of superposition) in orthogonal orientations corresponding to
those of Fig. 4. The bottom panel lists residues that have atoms in
contact with a single OC252 or anilinoquinazoline molecule. Filled
ellipses represent the approximate location inhibitor molecules that
give rise to the contacts. Open ellipses represent the relative position of
the second molecule of the pair of bound inhibitors. Residues in contact
are grouped within their respective subunits.
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pocket of FBPase could be an effective target, even if prevailing
conditions in vivo do not favor the I-state.
Assays used to screen for potent inhibition of FBPase have
employed concentrations of F16P2 as high as 500 M (24).
These conditions exclude inhibitors that compete with F16P2
and bias the screen in favor of ligands that inhibit FBPase only
in the presence of bound F16P2. Although this strategy has led
to the discovery of molecules that do not bind to the active site,
it has the disadvantage of selecting ligands that require high
concentrations of F16P2 for potent inhibition. For instance, I0.5
is low (6 M) for OC252 in the presence of 100 M F16P2 but
rises to 70 M at a concentration of 2 M F16P2. Hence, an
initial screen using high concentrations of F16P2 may identify
new leads that target the central allosteric site of FBPase, but
further kinetic analysis at low concentrations of F16P2 may be
more appropriate in optimizing the lead compound as a potent
inhibitor in vivo.
The above also assumes that no consequence beyond inhibi-
tion will result from the ligation of the central allosteric pocket
of FBPase. Such an assumption, however, may be unwar-
ranted. Available sequences of FBPase reveal Asp187 as an
invariant residue. The mutation of Asp187 to alanine has only a
modest effect on the functional properties of FBPase (36). Its
mutation to phenylalanine has no greater effect on FBPase
function than that due to the alanine mutation.3 What selective
pressure then retains aspartate at position 187 and is it just
coincidence that OC252 hydrogen-bonds to this side chain? The
conservation of Asp187 suggests a role in the recognition of a
natural effector. Several reports (3740) are in the literature,
for instance, regarding interactions between FBPase and aldol-
ase. The C-terminal residues of aldolase are putatively essen-
tial to these interactions, and the consensus sequences for both
type A and B isozymes of aldolase end in tyrosine, which
matches residue 4 of OC252. Hence, a potential drug may have
to compete with a natural effector for the central allosteric
pocket, or possibly FBPase itself may act as an effector in some
other physiological process. Further clarification of these issues
may be critical to the success of efforts to develop drugs that
effectively target FBPase.
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